Cardiff Oncology annual revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Cardiff Oncology Revenue Growth & History (CRDF)
Cardiff Oncology reported $593,000 in revenue for fiscal 2025, a decrease of 13.18% from the previous fiscal year.
View full Cardiff Oncology company overviewCardiff Oncology annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $593,000 | −$90,000 | −13.18% |
| 2024 | 2024-12-31 | $683,000 | $195,000 | +39.96% |
| 2023 | 2023-12-31 | $488,000 | $102,000 | +26.42% |
| 2022 | 2022-12-31 | $386,000 | $27,000 | +7.52% |
| 2021 | 2021-12-31 | $359,000 | −$7,000 | −1.91% |
| 2020 | 2020-12-31 | $366,000 | $121,368 | +49.61% |
| 2019 | 2019-12-31 | $244,632 | −$133,693 | −35.34% |
| 2018 | 2018-12-31 | $378,325 | −$127,079 | −25.14% |
| 2017 | 2017-12-31 | $505,404 | $124,332 | +32.63% |
| 2016 | 2016-12-31 | $381,072 | $68,260 | +21.82% |
| 2015 | 2015-12-31 | $312,812 | $32,634 | +11.65% |
| 2014 | 2014-12-31 | $280,178 | $20,932 | +8.07% |
| 2013 | 2013-12-31 | $259,246 | −$191,158 | −42.44% |
| 2012 | 2012-12-31 | $450,404 | $192,708 | +74.78% |
| 2011 | 2011-12-31 | $257,696 | — | — |
Cardiff Oncology quarterly revenue
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $104,000 | −$17,000 | −14.05% |
| Q1 2026 | 2026-03-31 | $41,000 | −$68,000 | −62.39% |
| Q4 2025 | 2025-12-31 | $243,000 | $93,000 | +62.00% |
| Q3 2025 | 2025-09-30 | $120,000 | −$45,000 | −27.27% |
| Q2 2025 | 2025-06-30 | $121,000 | −$42,000 | −25.77% |
| Q1 2025 | 2025-03-31 | $109,000 | −$96,000 | −46.83% |
| Q4 2024 | 2024-12-31 | $150,000 | −$6,000 | −3.85% |
| Q3 2024 | 2024-09-30 | $165,000 | $24,000 | +17.02% |
| Q2 2024 | 2024-06-30 | $163,000 | $55,000 | +50.93% |
| Q1 2024 | 2024-03-31 | $205,000 | $122,000 | +146.99% |
| Q4 2023 | 2023-12-31 | $156,000 | $28,000 | +21.88% |
| Q3 2023 | 2023-09-30 | $141,000 | $48,000 | +51.61% |
| Q2 2023 | 2023-06-30 | $108,000 | $17,000 | +18.68% |
| Q1 2023 | 2023-03-31 | $83,000 | $9,000 | +12.16% |
| Q4 2022 | 2022-12-31 | $128,000 | −$5,000 | −3.76% |
| Q3 2022 | 2022-09-30 | $93,000 | $7,000 | +8.14% |
| Q2 2022 | 2022-06-30 | $91,000 | $23,000 | +33.82% |
| Q1 2022 | 2022-03-31 | $74,000 | $2,000 | +2.78% |
| Q4 2021 | 2021-12-31 | $133,000 | $14,000 | +11.76% |
| Q3 2021 | 2021-09-30 | $86,000 | −$50,000 | −36.76% |
| Q2 2021 | 2021-06-30 | $68,000 | $25,000 | +58.14% |
| Q1 2021 | 2021-03-31 | $72,000 | $4,000 | +5.88% |
| Q4 2020 | 2020-12-31 | $119,000 | $24,928 | +26.50% |
| Q3 2020 | 2020-09-30 | $136,000 | $84,313 | +163.12% |
| Q2 2020 | 2020-06-30 | $43,000 | $6,148 | +16.68% |
| Q1 2020 | 2020-03-31 | $68,000 | $5,979 | +9.64% |
| Q4 2019 | 2019-12-31 | $94,072 | $16,057 | +20.58% |
| Q3 2019 | 2019-09-30 | $51,687 | −$36,674 | −41.50% |
| Q2 2019 | 2019-06-30 | $36,852 | −$74,961 | −67.04% |
| Q1 2019 | 2019-03-31 | $62,021 | −$38,115 | −38.06% |
| Q4 2018 | 2018-12-31 | $78,015 | −$106,985 | −57.83% |
| Q3 2018 | 2018-09-30 | $88,361 | −$34,968 | −28.35% |
| Q2 2018 | 2018-06-30 | $111,813 | $9,802 | +9.61% |
| Q1 2018 | 2018-03-31 | $100,136 | $5,098 | +5.36% |
| Q4 2017 | 2017-12-31 | $185,000 | $117,000 | +172.06% |
| Q3 2017 | 2017-09-30 | $123,329 | $34,329 | +38.57% |
| Q2 2017 | 2017-06-30 | $102,011 | −$1,989 | −1.91% |
| Q1 2017 | 2017-03-31 | $95,038 | −$24,962 | −20.80% |
| Q4 2016 | 2016-12-31 | $68,000 | −$11,000 | −13.92% |
| Q3 2016 | 2016-09-30 | $89,000 | $31,000 | +53.45% |
| Q2 2016 | 2016-06-30 | $104,000 | $55,000 | +112.24% |
| Q1 2016 | 2016-03-31 | $120,000 | −$7,000 | −5.51% |
| Q4 2015 | 2015-12-31 | $79,000 | $23,000 | +41.07% |
| Q3 2015 | 2015-09-30 | $58,000 | $1,000 | +1.75% |
| Q2 2015 | 2015-06-30 | $49,000 | −$7,000 | −12.50% |
| Q1 2015 | 2015-03-31 | $127,000 | $16,000 | +14.41% |
| Q4 2014 | 2014-12-31 | $56,000 | $9,000 | +19.15% |
| Q3 2014 | 2014-09-30 | $57,000 | $13,000 | +29.55% |
| Q2 2014 | 2014-06-30 | $56,000 | $7,000 | +14.29% |
| Q1 2014 | 2014-03-31 | $111,000 | −$8,000 | −6.72% |
| Q4 2013 | 2013-12-31 | $47,000 | −$116,000 | −71.17% |
| Q3 2013 | 2013-09-30 | $44,000 | −$168,000 | −79.25% |
| Q2 2013 | 2013-06-30 | $49,000 | $7,000 | +16.67% |
| Q1 2013 | 2013-03-31 | $119,000 | $85,000 | +250.00% |
| Q4 2012 | 2012-12-31 | $163,000 | $129,249 | +382.95% |
| Q3 2012 | 2012-09-30 | $212,000 | $157,000 | +285.45% |
| Q2 2012 | 2012-06-30 | $42,000 | −$37,863 | −47.41% |
| Q1 2012 | 2012-03-31 | $34,000 | −$55,082 | −61.83% |
| Q4 2011 | 2011-12-31 | $33,751 | — | — |
| Q3 2011 | 2011-09-30 | $55,000 | — | — |
| Q2 2011 | 2011-06-30 | $79,863 | — | — |
| Q1 2011 | 2011-03-31 | $89,082 | — | — |
Cardiff Oncology revenue growth trends
Over the last five reported fiscal years, revenue grew from $366,000 to $593,000, a compound annual growth rate of 10.13%. Cardiff Oncology's latest reported quarter, Q2 2026, generated $104,000 in revenue, a decrease of 14.05% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Cardiff Oncology source filings ↗